Amid industry turbulence, Chroma raises fresh funding to edit the epigenome

Amid industry turbulence, Chroma raises fresh funding to edit the epigenome

Source: 
BioPharma Dive
snippet: 

Chroma Medicine, a Boston-based biotechnology startup focused on drugs that can alter the epigenome, revealed Wednesday that it has raised a $135 million Series B round.